Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Taltz ® (ixekizumab)
Taltz® (ixekizumab): What is the dosing regimen in axial spondyloarthritis?
160 mg at week 0, then 80 mg every 4 weeks.
The recommended dose is 160 mg (two 80 mg injections) by subcutaneous injection at Week 0, followed by 80 mg every 4 weeks.1
Consideration should be given to discontinuing treatment in patients who have shown no response after 16 to 20 weeks of treatment.1
Some patients with initially partial response may subsequently improve with continued treatment beyond 20 weeks.1
No dose adjustment is required in elderly patients (≥ 65years).1
There is limited information in subjects aged ≥ 75 years.1
Ixekizumab has not been studied in patients with renal or hepatic impairment. No dose recommendations can be made.1
Method of Administration
Ixekizumab is for subcutaneous injection. Injection sites may be alternated. If possible, areas of the skin that show psoriasis should be avoided as injection sites. The solution/the syringe must not be shaken.1
After proper training in subcutaneous injection technique, patients may self-inject ixekizumab if a healthcare professional determines that it is appropriate. However, the physician should ensure appropriate follow-up of patients. Comprehensive instructions for administration are given in the package leaflet.1
1. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Date of Last Review: June 17, 2020